Early use of ECMO devices does not improve outcomes in people with cardiogenic shock

Professional, doctor. Scientist with microscope

The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) devices to support adults with rapidly deteriorating or severe cardiogenic shock was feasible but did not improve clinical outcomes compared to people who received early conservative therapy, according to late-breaking clinical trial results presented today at the American Heart Association’s Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov. 5–7, 2022, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

This wearable device could train your nervous system to deal with stress better

Previous article

Conservative state policies tied to higher mortality

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations